398 related articles for article (PubMed ID: 16010590)
41. The impact of p53 status on cellular sensitivity to antifolate drugs.
Lu X; Errington J; Curtin NJ; Lunec J; Newell DR
Clin Cancer Res; 2001 Jul; 7(7):2114-23. PubMed ID: 11448931
[TBL] [Abstract][Full Text] [Related]
42. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
[TBL] [Abstract][Full Text] [Related]
43. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K
Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072
[TBL] [Abstract][Full Text] [Related]
44. Folate and antifolate pharmacology.
Kamen B
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-30-S18-39. PubMed ID: 9420019
[TBL] [Abstract][Full Text] [Related]
45. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.
Curtin NJ; Bowman KJ; Turner RN; Huang B; Loughlin PJ; Calvert AH; Golding BT; Griffin RJ; Newell DR
Br J Cancer; 1999 Aug; 80(11):1738-46. PubMed ID: 10468290
[TBL] [Abstract][Full Text] [Related]
46. Thermodynamic stabilization of nucleotide binding to thymidylate synthase by a potent benzoquinazoline folate analogue inhibitor.
Chen CH; Davis RA; Maley F
Biochemistry; 1996 Jul; 35(26):8786-93. PubMed ID: 8679643
[TBL] [Abstract][Full Text] [Related]
47. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
Van Triest B; Pinedo HM; Giaccone G; Peters GJ
Ann Oncol; 2000 Apr; 11(4):385-91. PubMed ID: 10847455
[TBL] [Abstract][Full Text] [Related]
48. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line.
Lu K; Yin MB; McGuire JJ; Bonmassar E; Rustum YM
Biochem Pharmacol; 1995 Jul; 50(3):391-8. PubMed ID: 7646540
[TBL] [Abstract][Full Text] [Related]
49. Probing the folate-binding site of human thymidylate synthase by site-directed mutagenesis. Generation of mutants that confer resistance to raltitrexed, Thymitaq, and BW1843U89.
Tong Y; Liu-Chen X; Ercikan-Abali EA; Zhao SC; Banerjee D; Maley F; Bertino JR
J Biol Chem; 1998 Nov; 273(47):31209-14. PubMed ID: 9813027
[TBL] [Abstract][Full Text] [Related]
50. Recent advances in the study of rTS proteins. rTS expression during growth and in response to thymidylate synthase inhibitors in human tumor cells.
Dolnick BJ; Lu K; Yin MB; Rustum YM
Adv Enzyme Regul; 1997; 37():95-109. PubMed ID: 9381988
[TBL] [Abstract][Full Text] [Related]
51. Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.
Mitrovski B; Pressacco J; Mandelbaum S; Erlichman C
Cancer Chemother Pharmacol; 1994; 35(2):109-14. PubMed ID: 7987985
[TBL] [Abstract][Full Text] [Related]
52. Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines.
Bijnsdorp IV; Kruyt FA; Fukushima M; Smid K; Gokoel S; Peters GJ
Cancer Sci; 2010 Feb; 101(2):440-7. PubMed ID: 19886911
[TBL] [Abstract][Full Text] [Related]
53. The effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor on the expression of thymidine phosphorylase.
De Bruin M; Van Capel T; Smid K; Fukushima M; Hoekman K; Pinedo HM; Peters GJ
Eur J Pharmacol; 2004 May; 491(2-3):93-9. PubMed ID: 15140625
[TBL] [Abstract][Full Text] [Related]
54. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Li WW; Tong WP; Bertino JR
Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
[TBL] [Abstract][Full Text] [Related]
55. Accumulation of DNA strand breaks in cells exposed to methotrexate or N10-propargyl-5,8-dideazafolic acid.
Lorico A; Toffoli G; Boiocchi M; Erba E; Broggini M; Rappa G; D'Incalci M
Cancer Res; 1988 Apr; 48(8):2036-41. PubMed ID: 3349474
[TBL] [Abstract][Full Text] [Related]
56. Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
Marverti G; Ligabue A; Paglietti G; Corona P; Piras S; Vitale G; Guerrieri D; Luciani R; Costi MP; Frassineti C; Moruzzi MS
Eur J Pharmacol; 2009 Aug; 615(1-3):17-26. PubMed ID: 19446547
[TBL] [Abstract][Full Text] [Related]
57. Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.
Curtin NJ; Harris AL; Aherne GW
Cancer Res; 1991 May; 51(9):2346-52. PubMed ID: 2015598
[TBL] [Abstract][Full Text] [Related]
58. Mechanism of action of 5,8-dideazaisofolic acid and other quinazoline antifols in human colon carcinoma cells.
McGuire JJ; Sobrero AF; Hynes JB; Bertino JR
Cancer Res; 1987 Nov; 47(22):5975-81. PubMed ID: 3664501
[TBL] [Abstract][Full Text] [Related]
59. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
[TBL] [Abstract][Full Text] [Related]
60. Variable expression of RFC1 in human leukemia cell lines resistant to antifolates.
Kobayashi H; Takemura Y; Ohnuma T
Cancer Lett; 1998 Feb; 124(2):135-42. PubMed ID: 9500202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
